Mundipharma International has a proven track record of commercialising innovation in Europe. We have a unique insight into the realities of the European pharmaceutical market and have the resources and internal expertise to help our network of independent associated companies successfully bringing products to market.

Dr Rebecca Forster, Business Development Manager
 

Case studies

At Mundipharma International we pride ourselves on our commercial programmes and our ability to assist our independent associated companies in the delivery of innovative new products to market.

Horizon Pharma - Rheumatoid Arthritis

Horizon Pharma specialises in the development and commercialisation of medicines to treat chronic inflammation and pain-related diseases.

Rheumatoid arthritis (RA) is a chronic or long-term, progressive, inflammatory disease which causes damage to the cartilage and bone in the affected joints.1 Recent research involving 1172 patients from 21 European countries found that more than eight in ten patients suffering from morning stiffness and pain due to RA at least 3 times a week say it has a significant impact on their quality of life. 2

Lodotra® (modified-release prednisone) is an innovative programmed-release formulation for the treatment of rheumatoid arthritis in adults, particularly those who suffer from accompanied morning stiffness.

Read the full Horizon Pharma case study

Collaboration with Horizon Pharma

March 2009, Lodotra® (modified-release prednisone) was approved in Europe for the treatment of rheumatoid arthritis and associated morning stiffness. The same year, exclusive rights for the distribution of Lodotra® were granted in Europe, excluding Germany and Austria.

November 2010, an exclusive distribution and supply agreement was signed with Horizon for the commercialisation of Lodotra® in Australia, China, Hong-Kong, Indonesia, Korea, Malaysia, New Zealand, Philippines, Singapore, South Africa, Taiwan, Thailand and Vietnam.

April 2011, the distribution rights for Lodotra® were acquired in Germany.

Lodotra® is approved for the treatment of RA and associated morning stiffness in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Sweden and the United Kingdom and is currently available in the following European countries: Austria, Belgium, Denmark, Finland, Germany, Italy, Luxembourg, the Netherlands, Norway, Poland, and the United Kingdom.

Studies are planned to investigate the use of Lodotra® in other indications in which IL-6 cytokines play a role.

To bring your product to life, please Contact us.

Back

Skye Pharma - Asthma

SkyePharma, a leading speciality drug delivery company, offers extensive know how and experience in development of inhalation products.

With around 300 million asthma patients worldwide, this condition represents a significant challenge for public health. In 2003 it was estimated that the total cost of asthma in Europe is €17.7bn per year, and productivity lost to poor asthma control was estimated at €9.8bn per annum. 3, 4

Our latest collaboration with SkyePharma Plc, UK

flutiform® is a novel combination therapy in development for the treatment of asthma which brings together two well established compounds, a potent inhaled corticosteroid, fluticasone propionate and a long-acting β2 agonist, formoterol fumarate, in a single aerosol inhaler.

Read the full Skye Pharma - Asthma case study

In September 2006, an exclusive agreement was made with SkyePharma to develop and market flutiform® for asthma across multiple markets in Europe and other territories.

To bring your product to life, please Contact us.

Back

A collaboration with Astellas Pharma, Germany

Astellas Pharma has a strong presence in the European market, and is a major player in three key areas: transplantation, urology and dermatology.

Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world. It is also incurable, and the treatment goal is to stabilise the cancer in order for patients to live their lives without symptoms.

Levact▼®/Ribomustin®/Ribovact® (bendamustine) is a novel dual structured chemotherapy agent. It is currently licensed in the EU for the use in certain types of multiple myeloma, chronic lymphocytic leukaemia (CLL) and indolent non-Hodgkin’s lymphoma.

Read the full collaboration with Astellas Pharma, Germany case study

In October 2006, Mundipharma acquired exclusive rights to develop and commercialise the anti-cancer compound Levact▼®/Ribomustin®/Ribovact®.

Levact▼®/Ribomustin® Ribovact® is currently licensed across Europe for the use in certain types of multiple myeloma, CLL and indolent non-Hodgkin’s lymphoma.

To bring your product to life, please Contact us.

Back

References

  1. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003; 42 (Suppl 2); ii11 - ii16
  2. Ipsos MORI Rheumatoid Arthritis patient survey Wave 1 and 2 (Wave 1: May 2010 Participants: 750 adults; Wave 2: December 2010. Participants 442 adults)
  3. http://chestjournal.chestpubs.org/content/130/1_suppl/4S.full.html
  4. White Book of the European Respiratory Society (ERS)

Be a partner

Your key contact persons are:

Dr Rebecca Forster - Addiction therapy

Ann Dugdale - Alliance Management

Jim MacDonald-Clink - Respiratory, inflammation and other therapy areas

Allen Downs - Pain